Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ASTRA: A Phase 3 Multi-center, Randomized, Double-Masked, Prospective Study of AURN001 in Subjects With Corneal Edema Secondary to Corneal Endothelial Dysfunction (ABA-3)

NCT07368959 is registered in ClinicalTrials.gov with Aurion Biotech as lead sponsor.

NCT NCT07368959
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07368959 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ASTRA: A Phase 3 Multi-center, Randomized, Double-Masked, Prospective Study of AURN001 in Subjects With Corneal Edema Secondary to Corneal Endothelial Dysfunction (ABA-3)
Lead sponsor
Aurion Biotech
Phase
Phase 3
Overall status
Active, not recruiting
Start date
February 19, 2026
Completion date
January 31, 2028
Enrollment
130 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

corneal edema, corneal endothelial dysfunction, fuchs endothelial corneal dysfunction, pseudophakic bullous keratopathy (pbk)